Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) Shares Outstanding (Weighted Average): 2023-2025

Historic Shares Outstanding (Weighted Average) for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $42.1 million.

  • Zenas BioPharma's Shares Outstanding (Weighted Average) rose 0.76% to $42.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.1 million, marking a year-over-year increase of 0.76%. This contributed to the annual value of $41.8 million for FY2024, which is 57.36% up from last year.
  • Latest data reveals that Zenas BioPharma reported Shares Outstanding (Weighted Average) of $42.1 million as of Q3 2025, which was up 0.66% from $41.8 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Shares Outstanding (Weighted Average) high stood at $42.1 million for Q3 2025, and its period low was $26.6 million during Q4 2023.
  • Over the past 3 years, Zenas BioPharma's median Shares Outstanding (Weighted Average) value was $41.8 million (recorded in 2024), while the average stood at $37.6 million.
  • Data for Zenas BioPharma's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 57.53% (in 2025) over the last 5 years.
  • Zenas BioPharma's Shares Outstanding (Weighted Average) (Quarterly) stood at $26.6 million in 2023, then skyrocketed by 57.36% to $41.8 million in 2024, then rose by 0.76% to $42.1 million in 2025.
  • Its last three reported values are $42.1 million in Q3 2025, $41.8 million for Q2 2025, and $41.8 million during Q1 2025.